EP1845967A4 - A method of modulating t cell functioning - Google Patents

A method of modulating t cell functioning

Info

Publication number
EP1845967A4
EP1845967A4 EP06718328A EP06718328A EP1845967A4 EP 1845967 A4 EP1845967 A4 EP 1845967A4 EP 06718328 A EP06718328 A EP 06718328A EP 06718328 A EP06718328 A EP 06718328A EP 1845967 A4 EP1845967 A4 EP 1845967A4
Authority
EP
European Patent Office
Prior art keywords
modulating
cell functioning
functioning
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06718328A
Other languages
German (de)
French (fr)
Other versions
EP1845967A2 (en
Inventor
Lawrence Steinman
M Platten
Peggy Pui-Kay Ho
Michael L Selley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to EP10007472A priority Critical patent/EP2253313A1/en
Publication of EP1845967A2 publication Critical patent/EP1845967A2/en
Publication of EP1845967A4 publication Critical patent/EP1845967A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP06718328A 2005-01-14 2006-01-12 A method of modulating t cell functioning Ceased EP1845967A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10007472A EP2253313A1 (en) 2005-01-14 2006-01-12 Tranilast as modulator of T cell functioning for use in the treatment of autoimmune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64450205P 2005-01-14 2005-01-14
PCT/US2006/001241 WO2006076580A2 (en) 2005-01-14 2006-01-12 A method of modulating t cell functioning

Publications (2)

Publication Number Publication Date
EP1845967A2 EP1845967A2 (en) 2007-10-24
EP1845967A4 true EP1845967A4 (en) 2008-03-05

Family

ID=36678226

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10007472A Withdrawn EP2253313A1 (en) 2005-01-14 2006-01-12 Tranilast as modulator of T cell functioning for use in the treatment of autoimmune diseases
EP06718328A Ceased EP1845967A4 (en) 2005-01-14 2006-01-12 A method of modulating t cell functioning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10007472A Withdrawn EP2253313A1 (en) 2005-01-14 2006-01-12 Tranilast as modulator of T cell functioning for use in the treatment of autoimmune diseases

Country Status (10)

Country Link
EP (2) EP2253313A1 (en)
JP (1) JP2008526983A (en)
KR (1) KR20070098916A (en)
CN (1) CN101232878A (en)
AU (1) AU2006204871A1 (en)
BR (1) BRPI0605925A2 (en)
CA (1) CA2594460A1 (en)
IL (1) IL184523A0 (en)
WO (1) WO2006076580A2 (en)
ZA (1) ZA200706751B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2030617A1 (en) * 2007-08-17 2009-03-04 Sygnis Bioscience GmbH & Co. KG Use of tranilast and derivatives thereof for the therapy of neurological conditions
FR3055548B1 (en) * 2016-09-05 2018-09-28 Metabrain Research USE OF METABOLITES OF TRYPTOPHAN IN THE TREATMENT OF MUSCLE ATROPHY
CN110607335B (en) * 2018-06-14 2021-08-03 中国科学院微生物研究所 Biosynthesis method of nicotinamide adenine dinucleotide compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
WO2006053390A1 (en) * 2004-11-17 2006-05-26 Angiogen Pharmaceuticals Pty. Ltd. A method of modulating b cell functioning

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640710B2 (en) 1973-01-18 1981-09-22
US20050239892A1 (en) * 2003-11-21 2005-10-27 Trustees Of Tufts College Therapeutic avenathramide compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
WO2006053390A1 (en) * 2004-11-17 2006-05-26 Angiogen Pharmaceuticals Pty. Ltd. A method of modulating b cell functioning

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FALLARINO F ET AL: "T cell apoptosis by tryptophan catabolism", CELL DEATH AND DIFFERENTIATION, vol. 9, no. 10, 2002, pages 1069 - 1077, XP002463098 *
TERNESS P ET AL: "Inhibition of allogeneic T cell proliferation by indoleamine-2,3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 196, no. 4, 19 August 2002 (2002-08-19), pages 447 - 457, XP002219409, ISSN: 0022-1007 *
WIDNER B ET AL: "Tryptophan degradation to control T-cell responsiveness", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 5, May 2000 (2000-05-01), pages 250, XP004198157, ISSN: 0167-5699 *
WIRLEITNER B ET AL: "Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects", CURRENT MEDICINAL CHEMISTRY, vol. 10, no. 16, 2003, pages 1581 - 1591, XP002463099 *

Also Published As

Publication number Publication date
EP2253313A1 (en) 2010-11-24
KR20070098916A (en) 2007-10-05
IL184523A0 (en) 2008-12-29
AU2006204871A1 (en) 2006-07-20
EP1845967A2 (en) 2007-10-24
BRPI0605925A2 (en) 2009-05-26
WO2006076580A2 (en) 2006-07-20
CA2594460A1 (en) 2006-07-20
CN101232878A (en) 2008-07-30
WO2006076580A3 (en) 2007-07-12
ZA200706751B (en) 2008-10-29
JP2008526983A (en) 2008-07-24

Similar Documents

Publication Publication Date Title
ZA200704871B (en) A method of modulating B cell functioning
EP1924146A4 (en) A method for cell implantation
EP1880546A4 (en) Strategies for scheduling bandwidth-consuming media events
GB0522477D0 (en) Modulator
ZA200605397B (en) Reactor sealing methods
HK1141251A1 (en) A method for enhancing cell response
EP1891437A4 (en) Method of profiling a cell population
IL193841A0 (en) Methods for modulating bladder function
IL184262A (en) Cell culture method
EP1766389A4 (en) A method of cell isolation
ZA200810214B (en) A teaching aid
EP2231137A4 (en) Method of modulating membrane potential of a cell
EP1788077B8 (en) A method for creating cell clusters
GB0519848D0 (en) A method of trading
EP1877201A4 (en) Methanogenesis stimulated by isolated anaerobic consortia
GB0607671D0 (en) Method for modulating a signal
EP1940450A4 (en) Method of modulation
IL184523A0 (en) A method of modulating t cell functioning
AP1887A (en) An electrode and a method for forming an electrode
GB2424776B (en) Method for switching a power amplifier
TWI371487B (en) A fast method of transforming competent cells
GB0411920D0 (en) A face seal
GB0625492D0 (en) A teaching aid
EP1871871A4 (en) Method for activating cd4 t cells
GB0401019D0 (en) A seal

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070814

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105280

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 209/20 20060101ALI20080116BHEP

Ipc: A61P 37/04 20060101ALI20080116BHEP

Ipc: A61P 37/02 20060101ALI20080116BHEP

Ipc: A61P 37/00 20060101ALI20080116BHEP

Ipc: A61K 31/195 20060101AFI20070823BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080131

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100828

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105280

Country of ref document: HK